- Home
- Equipment
- south korea
- drug candidate
Refine by
Drug Candidate Equipment Supplied In South Korea
8 equipment items found
Manufactured by:JD Bioscience Inc. (JDB) based inBuk-gu, SOUTH KOREA
JDB is developing a novel drug candidate for heart disease that can rescue heart function at a cellular level, and can eventually help improving heart ...
Manufactured by:JD Bioscience Inc. (JDB) based inBuk-gu, SOUTH KOREA
JDB is developing a novel drug candidate for acute pancreatitis that can effectively reduce inflammation of the pancreas by modulating mitochondrial functions in pancreatic ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
DearDTI presents drug candidates with a good efficacy by predicting the binding affinity, based on information about the compound-protein ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
On July 29, 2020, Vivozon applied for a patent for a second pipeline, VVZ-2471, and is currently conducting non-clinical toxicity studies. VVZ-2471 is a new drug candidate for treating chronic pain including neuropathic pain. Recently, the prevention and treatment potential of drug (morphine) addiction, anxiety, and depression have also ...
Manufactured by:LISCure Biosciences Inc. based inSeongnam-si, SOUTH KOREA
The LMT (LISCure Microbiology-based Technology) platform is an innovative tool to keep discovering and analyzing microbial and genome-based drug candidates. LMT (LISCure Microbiology-based Technology) Platform Consists of the Therapeutic Screening Platform, Microbial Optimization Platform, and Microbiome Database ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
MolEQ designs novel compounds by optimizing multiple properties such as efficacy and toxicity of a lead ...
Manufactured by:JD Bioscience Inc. (JDB) based inBuk-gu, SOUTH KOREA
NASH, an advanced form of non-alcoholic fatty liver disease (NAFLD), can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Genetic factors, environmental factors, and microbiome alterations are mainly involved in disease progression. Experts estimated that 24% of U.S. adults have NAFLD and more than 6.5% of them have NASH (NIH report, 2021). 20~30% of patients with NASH ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology. It specializes in genome data analysis, biomarker prediction, molecule selection and optimization. DEARGEN discovers new disease targets with Dr.UG and further realizes precision medicine by designing small molecules for new ...